<DOC>
	<DOCNO>NCT00761696</DOCNO>
	<brief_summary>The primary objective study : - To determine safety maximum tolerate dose ( MTD ) IPI-926 - To examine pharmacokinetic parameter IPI-926 characterize major metabolite ( ) - To recommend dose schedule IPI-926 subsequent study</brief_summary>
	<brief_title>A Phase 1 Study IPI-926 Patients With Advanced and/or Metastatic Solid Tumor Malignancies</brief_title>
	<detailed_description>Study IPI-926-01 Phase 1 , open-label , dose-escalation study patient advance and/or metastatic solid tumor malignancy .</detailed_description>
	<mesh_term>Veratrum Alkaloids</mesh_term>
	<criteria>1 . Pathologically confirmed diagnosis solid tumor standard therapy proven provide clinical benefit available . 2 . ≥18 year age 3 . Life expectancy least 3 month . 4 . ECOG performance status 0 2 . 5 . Ability follow study protocol requirement . 6 . Voluntarily sign informed consent form 7 . Women childbearing potential ( WCBP ) , define sexually mature woman undergone hysterectomy tubal ligation naturally postmenopausal least 24 consecutive month , must negative serum urine pregnancy test prior treatment . All WCBP , sexually active male patient , partner patient must agree use adequate method birth control throughout study . 8 . Recovery &lt; /= Grade 1 baseline toxicity due prior treatment , exclude alopecia . 1 . Treatment follow therapy indicate : Any chemotherapy ( nitrosoureas mitomycin C ) , radiation therapy , surgery , hormonal therapy , investigational therapy within 4 week start IPI926 administration . Patients luteinizing hormone release hormone therapy . Any tyrosine kinase inhibitor ( e.g . erlotinib , imatinib ) within 2 week start IPI926 administration Nitrosoureas mitomycin C within 6 week start IPI926 administration . 2 . Inadequate hematologic function neutrophil count ( ANC ) &lt; 1,500 cells/mm3 , platelet count &lt; 100,000/mm3 , hemoglobin &lt; 9.0 g/dL ( may increase level transfusion long evidence active bleeding ) . 3 . Inadequate hepatic function aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 2.5 x upper limit normal ( ULN ) ; &gt; 5 x ULN attributable liver metastasis ; total bilirubin &gt; 1.5 x ULN . 4 . Inadequate renal function serum creatinine &gt; 1.5 x ULN . 5 . Uncontrolled hypomagnesemia hypokalemia , define ≥ Grade 3 despite adequate electrolyte supplementation . 6 . Baseline QTcF &gt; 450 msec men &gt; 470 msec woman . 7 . Concurrent treatment agent know prolong QTc interval . 8 . Prior surgery affect drug absorption gastrointestinal dysfunction could alter drug absorption ( e.g . gastric bypass , Whipple procedure , gastrectomy ) . 9 . History stroke , unstable angina , myocardial infarction , ventricular arrhythmia require medication mechanical control within last 6 month . 10 . Venous thromboembolic event ( e.g . pulmonary embolism deep vein thrombosis ) require anticoagulation meet follow criterion exclude : stable dose anticoagulation &lt; 1 month Grade 2 , 3 4 hemorrhage last 30 day experience continued symptom venous thromboembolic event ( e.g . continue dyspnea oxygen requirement ) *Past venous thromboembolic event meet three criterion eligible participation . 11 . History seizure within last 10 year seizure disorder require antiepileptic medication . 12 . Concurrent treatment medication know low seizure threshold . 13 . Concurrent administration medication food know inhibit induce CYP3A activity clinically relevant degree . 14 . Presence active infection systemic use antibiotic within 72 hour treatment . 15 . Significant comorbid condition disease judgment Investigator would place patient undue risk interfere study . 16 . Known immunodeficiency virus ( HIV ) positivity . 17 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>solid tumor malignancy</keyword>
</DOC>